Trial Profile
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms SERENE-UC
- Sponsors AbbVie; AbbVie Germany
- 11 Mar 2023 Results assessing the impact of immunogenicity and improving prediction of trough concentrations of Adalimumab in patients with Crohns Disease and Ulcerative Colitis from SERENE CD (NCT02065570) and SERENE UC (NCT02065622) studies, published in the Clinical Pharmacokinetics..
- 25 Feb 2022 Results published in the Gastroenterology
- 01 Feb 2022 According to an AbbVie media release, results from this study will be presented at the 17th Congress of European Crohn's and Colitis Organisation (ECCO), 2022.